Idogen AB ("Idogen" or the "Company") has applied for and received conditional approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is June 4, 2020.
Idogen AB has applied for and received conditional approval for admission to trading on Nasdaq First North Growth Market. The first day of trading in the Company's share on Nasdaq First North Growth Market is June 4, 2020. Trading in the Company's share on Spotlight Stock Market will end and the last day of trading on Spotlight Stock Market is on June 3, 2020. Nasdaq's decision is conditional upon (i) that nothing occurs in connection with the change of listing venue that could lead to a different assessment by Nasdaq, (ii) that the Company fulfills the disclosure requirement in accordance with Nasdaq First North Growth Market Rulebook, and (iii) that the Company, no later than two days before the first day of trading, updates its website in accordance with Nasdaq First North Growth Market Rulebook.
"The listing on Nasdaq First North Growth Market has been an important and prioritized target for Idogen in 2020 and we are happy that we today can announce that the Company fulfills all Nasdaq's requirements and thus has obtained a conditional approval. Nasdaq is a global well-known brand that enables increased visibility in the stock market and facilitates institutional and international investors to become shareholders in the Company. I also want to take the opportunity to thank Spotlight Stock Market for good cooperation over the years", comments Anders Karlsson, CEO of Idogen.
Idogen's stock will continue to be traded under the ticker IDOGEN with ISIN code SE0014428561. As previously announced, the Company's ISIN code will change as a result of the consolidation of shares (1:10). No new shares will be issued in conjunction with the Company's shares being admitted to trading on Nasdaq First North Growth Market and the Company's shareholders do not need to take any actions in connection with the change of listing venue. In Connection with the listing of shares on Nasdaq First North Growth Market, Idogen has prepared a supplementary document that is available on the Company's website, www.idogen.com. The supplementary document shall be read as a supplement to the prospectus that the Company published in connection with the rights issue of shares that the board resolved on January 28, 2020, and that was approved by the Extraordinary General Meeting on February 17, 2020. The supplementary document is not a prospectus, has not been reviewed or approved by any regulatory authority and does not contain and offer of shares or other financial instruments.
Idogen has appointed Erik Penser Bank as the Company's Certified Adviser on Nasdaq First North Growth Market.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Tel: +46 70 918 00 10
The information was submitted for publication, through the agency of the contact persons set out above, on May 20, 2020.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of haemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.